Cigna has been looking to sell its Medicare Advantage business, perhaps as a way to fend off antitrust objection to the deal.
Cigna and Humana are negotiations about a deal that would combine two of the largest private U.S. health insurers, the Wall Street Journal is reporting.
“The companies are discussing at stock-and-cash dela that could be finalized by the end of the year,” the newspaper reported in an article posted at 12:05 p.m.
Several media outlets have reported that Cigna has been looking to sell its Medicare Advantage (MA) business, a move that might help fend off antitrust roadblocks to the combination.
According to KFF (formerly known as the Kaiser Family Foundation), Cigna has a relatively small slice of the growing MA market with 600,000 MA enrollees that account for 2% of the Medicare beneficiaries enrolled in MA plans. Humana, with 5.5 million MA enrollees has 18% of the market and is the second largest MA insurer after UnitedHealthcare.
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More